SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2006 / Cilt: 6 - Sayı: 2

Tiazid ve tiazid potasyum tutucu diüretik kombinasyonlarının fibrinolitik sistem parametreleri üzerine etkileri

The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters

Timuçin KAŞİFOĞLU
Ahmet Uğur YALÇIN
Pages
143–147
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Treatment with HCT-spironolactone caused an increase in PAI-I (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study investigates whether the combination of thiazides with an aldosterone antagonist can decrease their negative effects on the fibrinolytic activity.Methods: Twenty-eight hypertensive patients (20 men, 8 women) visiting our hypertension unit were included in the study.
📊
Key Findings & Data:The control group consisted of age- and gender-matched 9 normotensive healthy individuals.
💡
Conclusion & Impact:Results: Treatment with HCT-spironolactone caused an increase in PAI-I (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study investigates whether the combination of thiazides with an aldosterone antagonist can decrease their negative effects on the fibrinolytic activity.Methods: Twenty-eight hypertensive patients (20 men, 8 women) visiting our hypertension unit were included in the study. The control group consisted of age- and gender-matched 9 normotensive healthy individuals. The patients in the 1st group (7 men, 2 women, mean age 48.55±6.14 years) were given 50 mg hydrochlorothiazide (HCT), whereas patients in the 2nd group (7 men, 2 women, mean age 48±6.3 years) received a combination of 50 mg HCT and 5 mg amyloride and the 3rd group (7 men, 3 women, mean age 48.2±7.25 years) took 50 mg HCT and 50 mg spironolactone for a period of 2 weeks. The plasminogen activator inhibitor (PAI)-I, tissue plasminogen activator (t-PA) and PAI-I/t-PA ratio were assessed before and after treatment. Results: Treatment with HCT-spironolactone caused an increase in PAI-I (p

Özet

Amaç: Bu çalışmada tiazidlerin aldosteron antagonistleri ile kombine edilmelerinin, fibrinolitik aktivite üzerine tiazidlerin yaptığı olumsuz etkileri azaltabileceğinin araştırılması hedeflenmiştir. Yöntemler: Bu çalışmaya hipertansiyon ünitemize başvuran 28 hipertansif hasta (20 erkek, 8 bayan) dahil edilmiştir. Kontrol grubu hastalara uygun yaş ve cinsiyetle eşleştirilen 9 normotansif sağlıklı bireyi içeriyordu. Birinci gruba (7 erkek, 2 kadın, ortalama yaş 48.55±6.14) 50mg hidroklortiazid (HCT), 2. gruba (7 erkek, 2 kadın, ortalama yaş 48±6.3) 50mg HCT ve 5mg amilorid kombinasyonu, 3. gruba (7 erkek, 3 kadın, ortalama yaş 48.2±7.25) 50mg HCT ve 50mg spironolakton kombinasyonu iki hafta süreyle verildi. Bulgular: Hidroklortiazid tedavisi plazminojen aktivatörü inhibitörü (PAI)-I ve PAI-I/doku plazminojen aktivatörü (t-PA) oranında artışa yol açmıştır (p

🔖

Cite This Article

KAŞİFOĞLU, T., YALÇIN, A. U. (2022). Tiazid ve tiazid potasyum tutucu diüretik kombinasyonlarının fibrinolitik sistem parametreleri üzerine etkileri. Anadolu Kardiyoloji Dergisi, Cilt: 6 - Sayı: 2, 143–147. https://ajindex.com/articles/437286

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Sakata K, Shirptani M, Yoshida H, Urano T, Takada Y, Takada A. Differential effects of enalapril and nitredipine on the fibrinolytic system in essential hypertension. Am Heart J 1999; 137: 1094-9
  2. Winther K, Gleerup G, Hedner T. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence? J Cardiovasc Pharmacol 1992; 19 Suppl 3: 21-4
  3. Nordt TK, Peter K, Ruef J, Kubler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999; 82 Suppl 1: 14-8
  4. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001; 103: 1936-41
  5. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor-1 in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1999; 227: 273-8
  6. Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction.Am J Hypertens 1995;8:909-14
  7. Sakata K, Pawlak R, Urano T, Takada A. Effects of a long term pharmacological interruption of the renin angiotensin system in essential hypertension. Pathophysiology of haemostasis and thrombosis. Pathophysiol Haemost Thromb 2002; 32: 67-75
  8. Lottermoser K, Weisser B, Hertfelder HJ, Wostmann B, Vetter H, Dusing R. Antihypertensive drug treatment and fibrinolytic function. Am J Hypertens 1998; 11: 378-84
  9. Brion P, Koiw E, Nowczynski W. The effect of intravenous infusion of valine 5 angiotensin II and other pressor agents on urinary electrolytes and corticoids including aldosterone. J Clin Invest 1961; 60: 338-42
  10. Brilla CG, Weber KT. Mineralocoricoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992; 120: 893-901
  11. Brilla CG, Matsubara LS, Weber KT. Antialdosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-75
  12. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17: 1152-6
  13. Grene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;